Apply for Biomedical Catalyst Funding worth £15 million

Innovate UK are committed to investing up to £15 million in projects to support UK registered businesses to develop innovative health or healthcare-focussed products, technologies and processes.

Competition Scope

The aim of this industry-led R&D competition is to support the development of innovative solutions to health and healthcare challenges, by funding industrial research and experimental development projects. The Biomedical Catalyst now incorporates the Digital Health Technology Catalyst and will support digital health projects. Your project can align with one or more of the following Innovation areas:

• biosciences
• advanced therapies (gene and cell therapies)
• diagnostic, medical technology and devices
• digital health
• independent living and wellbeing
• precision medicine
• preclinical technologies and drug target discovery
• therapeutic and medicine development

Your project can include:

• experimental evaluation (at laboratory scale)
• use of in vitro and in vivo models to evaluate proof of concept or safety
• exploring potential production mechanisms
• prototyping
• product development planning
• intellectual property protection
• a demonstration of clinical utility and effectiveness
• a demonstration of safety and efficacy (including phase 1 and 2 clinical trials)
• regulatory planning

You can view the full competition details on TBAT’s website here.

Eligibility Criteria

Projects must be led by a UK SME, and can apply as a single entity or as part of a collaborative project with partners. Your project must:

• have total project costs between £150,000 and £4 million
• not exceed a grant request of £2 million
• have at least 50% of the total project costs shared by the SMEs, if collaborative
• start by 1 December 2022
• end by 30 November 2025
• last between 6 months and 36 months
• carry out all of its project work in the UK
• intend to exploit the results from or in the UK

Biomedical Catalyst Funding Success

Grey Wolf Therapeutics approached TBAT in Spring 2020 to look at funding options for their technology, and for assistance to identify which Innovate UK funding opportunities would be suitable. After the latest round of Biomedical Catalyst funding was announced, the competition was selected due to their projects close alignment with the competition scope.

In January 2021, Grey Wolf Therapeutics were notified by Innovate UK that their application had been successful, and that they were being awarded their grant! You can read the full success story and how TBAT assisted Grey Wolf Therapeutics here.

Find out if your eligible to apply

TBAT Innovation Ltd are offering 1-to-1 consultations to help interested businesses decipher whether their project aligns with the competition scope, and whether their business is eligible to apply.

You can book a 1-to-1 appointment with one of the TBAT team here.

Alternatively, you can get in touch via their website contact form.